Telix Pharmaceuticals has acquired Vienna, Austria-based Dedicaid, a spin-off of the Medical University Vienna, for $1.2 million.
Telix said this acquisition expands its artificial intelligence (AI) capability through Dedicaid's clinical decision support software AI platform, which generates indication-specific applications from available datasets and is for use with PET and other imaging modalities. Each of the software's application is trained to predict outcomes such as the severity of disease, risk to the patient and/or inform treatment decisions.
The technology will add predictive capabilities to the company's AI platform, according to Telix.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
